Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,248 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer.
Camblin AJ, Pace EA, Adams S, Curley MD, Rimkunas V, Nie L, Tan G, Bloom T, Iadevaia S, Baum J, Minx C, Czibere A, Louis CU, Drummond DC, Nielsen UB, Schoeberl B, Pipas JM, Straubinger RM, Askoxylakis V, Lugovskoy AA. Camblin AJ, et al. Among authors: baum j. Clin Cancer Res. 2018 Jun 15;24(12):2873-2885. doi: 10.1158/1078-0432.CCR-17-2262. Epub 2018 Mar 16. Clin Cancer Res. 2018. PMID: 29549161
Rapid optimization and prototyping for therapeutic antibody-like molecules.
Xu L, Kohli N, Rennard R, Jiao Y, Razlog M, Zhang K, Baum J, Johnson B, Tang J, Schoeberl B, Fitzgerald J, Nielsen U, Lugovskoy AA. Xu L, et al. Among authors: baum j. MAbs. 2013 Mar-Apr;5(2):237-54. doi: 10.4161/mabs.23363. Epub 2013 Feb 7. MAbs. 2013. PMID: 23392215 Free PMC article.
MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors.
Fitzgerald JB, Johnson BW, Baum J, Adams S, Iadevaia S, Tang J, Rimkunas V, Xu L, Kohli N, Rennard R, Razlog M, Jiao Y, Harms BD, Olivier KJ Jr, Schoeberl B, Nielsen UB, Lugovskoy AA. Fitzgerald JB, et al. Among authors: baum j. Mol Cancer Ther. 2014 Feb;13(2):410-25. doi: 10.1158/1535-7163.MCT-13-0255. Epub 2013 Nov 26. Mol Cancer Ther. 2014. PMID: 24282274
Inhibition of IL1β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial.
Wong CC, Baum J, Silvestro A, Beste MT, Bharani-Dharan B, Xu S, Wang YA, Wang X, Prescott MF, Krajkovich L, Dugan M, Ridker PM, Martin AM, Svensson EC. Wong CC, et al. Among authors: baum j. Cancer Res. 2020 Dec 15;80(24):5597-5605. doi: 10.1158/0008-5472.CAN-19-3176. Epub 2020 Oct 6. Cancer Res. 2020. PMID: 33023946 Clinical Trial.
Targeting the IL1β Pathway for Cancer Immunotherapy Remodels the Tumor Microenvironment and Enhances Antitumor Immune Responses.
Diwanji R, O'Brien NA, Choi JE, Nguyen B, Laszewski T, Grauel AL, Yan Z, Xu X, Wu J, Ruddy DA, Piquet M, Pelletier MR, Savchenko A, Charette L, Rodrik-Outmezguine V, Baum J, Millholland JM, Wong CC, Martin AM, Dranoff G, Pruteanu-Malinici I, Cremasco V, Sabatos-Peyton C, Jayaraman P. Diwanji R, et al. Among authors: baum j. Cancer Immunol Res. 2023 Jun 2;11(6):777-791. doi: 10.1158/2326-6066.CIR-22-0290. Cancer Immunol Res. 2023. PMID: 37040466
Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study.
Felip E, de Braud FG, Maur M, Loong HH, Shaw AT, Vansteenkiste JF, John T, Liu G, Lolkema MP, Selvaggi G, Giannone V, Cazorla P, Baum J, Balbin OA, Wang LV, Lau YY, Scott JW, Tan DS. Felip E, et al. Among authors: baum j. J Thorac Oncol. 2020 Mar;15(3):392-403. doi: 10.1016/j.jtho.2019.10.006. Epub 2019 Oct 18. J Thorac Oncol. 2020. PMID: 31634667 Free article. Clinical Trial.
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Wise DR, Pachynski RK, Denmeade SR, Aggarwal RR, Deng J, Febles VA, Balar AV, Economides MP, Loomis C, Selvaraj S, Haas M, Kagey MH, Newman W, Baum J, Troxel AB, Griglun S, Leis D, Yang N, Aranchiy V, Machado S, Waalkes E, Gargano G, Soamchand N, Puranik A, Chattopadhyay P, Fedal E, Deng FM, Ren Q, Chiriboga L, Melamed J, Sirard CA, Wong KK. Wise DR, et al. Among authors: baum j. Prostate Cancer Prostatic Dis. 2024 Feb 10. doi: 10.1038/s41391-024-00798-z. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38341461
Tambjamines as Fast-Acting Multistage Antimalarials.
Kumar A, Li Y, Dodean RA, Roth A, Caridha D, Madejczyk MS, Jin X, Dennis WE, Lee PJ, Pybus BS, Martin M, Pannone K, Dinh HT, Blount C, Chetree R, DeLuca J, Evans M, Nadeau R, Vuong C, Leed S, Black C, Sousa J, Nolan C, Ceja FG, Rasmussen SA, Tumwebaze PK, Rosenthal PJ, Cooper RA, Rottmann M, Orjuela-Sanchez P, Meister S, Winzeler EA, Delves MJ, Matthews H, Baum J, Kirby RW, Burrows JN, Duffy J, Peyton DH, Reynolds KA, Kelly JX, Kancharla P. Kumar A, et al. Among authors: baum j. ACS Infect Dis. 2024 Nov 11. doi: 10.1021/acsinfecdis.4c00659. Online ahead of print. ACS Infect Dis. 2024. PMID: 39526703
DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish.
Klempner SJ, Sonbol MB, Wainberg ZA, Uronis HE, Chiu VK, Scott AJ, Iqbal S, Tejani MA, Chung V, Stilian MC, Thoma M, Zhang Y, Kagey MH, Baum J, Sirard CA, Altura RA, Ajani JA. Klempner SJ, et al. Among authors: baum j. J Clin Oncol. 2024 Oct 21:JCO2400410. doi: 10.1200/JCO.24.00410. Online ahead of print. J Clin Oncol. 2024. PMID: 39432867
1,248 results